Elanco Animal Health, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28414H1032
USD
21.99
-0.19 (-0.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Elanco Animal Health, Inc. stock-summary
stock-summary
Elanco Animal Health, Inc.
Pharmaceuticals & Biotechnology
Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.
Company Coordinates stock-summary
Company Details
2500 Innovation Way N , GREENFIELD IN : 46140-9163
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 85 Schemes (60.45%)

Foreign Institutions

Held by 194 Foreign Institutions (19.33%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. R. David Hoover
Independent Chairman of the Board
Mr. Jeffrey Simmons
President, Chief Executive Officer, Director
Mr. William Doyle
Director
Ms. Kapila Anand
Independent Director
Mr. John Bilbrey
Independent Director
Mr. Scott Ferguson
Independent Director
Mr. Art Garcia
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,241 Million
(Quarterly Results - Jun 2025)
Net Profit:
11 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9,464 Million (Small Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.54

stock-summary
Return on Equity

7.26%

stock-summary
Price to Book

1.40